Nancy J. Hutson's most recent trade in Biocryst Pharmaceuticals Inc. was a trade of 27,181 Automatic Stock Option Grant done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 27,181 | 27,181 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 12,500 | 99,138 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Sale of securities on an exchange or to another person at price $ 7.54 per share. | 13 Dec 2024 | 7,000 | 86,638 (0%) | 0% | 7.5 | 52,780 | Common Stock |
| Clearside Biomedical Inc | Nancy J. Hutson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 49,933 | 49,933 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 6,820 | 93,638 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Purchase of securities on an exchange or from another person at price $ 6.38 per share. | 20 May 2024 | 5,000 | 86,818 (0%) | 0% | 6.4 | 31,900 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 39,072 | 39,072 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 16,745 | 94,684 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Sale of securities on an exchange or to another person at price $ 8.04 per share. | 13 Jun 2023 | 12,866 | 81,818 (0%) | 0% | 8.0 | 103,443 | Common Stock |
| Clearside Biomedical Inc | Nancy J. Hutson | Director | Purchase of securities on an exchange or from another person at price $ 1.33 per share. | 17 Nov 2022 | 30,000 | 83,000 (0%) | 0% | 1.3 | 39,900 | Common Stock |
| Clearside Biomedical Inc | Nancy J. Hutson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 30,022 | 30,022 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 12,866 | 77,939 (0%) | 0% | 0 | Common Stock | |
| Clearside Biomedical Inc | Nancy J. Hutson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Oct 2021 | 25,000 | 0 | - | - | Stock Option (right to buy) | |
| Clearside Biomedical Inc | Nancy J. Hutson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 29 Oct 2021 | 25,000 | 38,000 (0%) | 0% | 2 | 50,000 | Common Stock |
| Clearside Biomedical Inc | Nancy J. Hutson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.09 per share. | 29 Oct 2021 | 15,000 | 53,000 (0%) | 0% | 2.1 | 31,350 | Common Stock |
| Clearside Biomedical Inc | Nancy J. Hutson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Oct 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Sale of securities on an exchange or to another person at price $ 15.40 per share. | 15 Oct 2021 | 105,000 | 65,073 (0%) | 0% | 15.4 | 1,617,000 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2021 | 30,000 | 0 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2021 | 30,000 | 0 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.22 per share. | 15 Oct 2021 | 30,000 | 170,073 (0%) | 0% | 3.2 | 96,600 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.13 per share. | 15 Oct 2021 | 30,000 | 125,073 (0%) | 0% | 5.1 | 153,900 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.91 per share. | 15 Oct 2021 | 30,000 | 95,073 (0%) | 0% | 2.9 | 87,300 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2021 | 30,000 | 0 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.71 per share. | 15 Oct 2021 | 15,000 | 140,073 (0%) | 0% | 1.7 | 25,650 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2021 | 15,000 | 0 | - | - | Automatic Stock Option Grant | |
| Clearside Biomedical Inc | Nancy J. Hutson | Director | Purchase of securities on an exchange or from another person at price $ 5.68 per share. | 16 Aug 2021 | 3,000 | 13,000 (0%) | 0% | 5.7 | 17,040 | Common Stock |
| Clearside Biomedical Inc | Nancy J. Hutson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Grant, award, or other acquisition of securities at price $ 15.77 per share. | 28 May 2021 | 317 | 65,073 (0%) | 0% | 15.8 | 4,999 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 40,000 | 40,000 | - | - | Automatic Stock Option Grant | |
| Clearside Biomedical Inc | Nancy J. Hutson | Director | Purchase of securities on an exchange or from another person at price $ 3.10 per share. | 12 Mar 2021 | 5,000 | 10,000 (0%) | 0% | 3.1 | 15,525 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Grant, award, or other acquisition of securities at price $ 10.78 per share. | 26 Feb 2021 | 463 | 64,756 (0%) | 0% | 10.8 | 4,991 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Grant, award, or other acquisition of securities at price $ 5.11 per share. | 30 Nov 2020 | 978 | 64,293 (0%) | 0% | 5.1 | 4,998 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Nancy J. Hutson | Director | Grant, award, or other acquisition of securities at price $ 4.15 per share. | 31 Aug 2020 | 1,204 | 63,315 (0%) | 0% | 4.2 | 4,997 | Common Stock |